TSVT - Novo Nordisk Buys 2seventy's Hemophilia A Program Divestiture Supports Exclusive Focus On Abecma | Benzinga
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO).
Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease.
The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology.